Ampersand Capital completed the investment in VIVEbiotech.

Ampersand Capital, a private equity firm, completed the investment in VIVEbiotech, a lentiviral vector contract development and manufacturing organization. Financial terms were not disclosed. “We are thrilled to welcome Ampersand as a key partner to accelerate VIVEbiotech’s ambitious growth plan while strengthening our flexible, plug-and-play platform. This partnership will play an important role in continuing to exceed our customers’ high expectations. The combination of Ampersand’s industry expertise and VIVE’s robust team will position VIVE as a market leader by expanding our capacity and unique capabilities,” Jon Alberdi, VIVEbiotech CEO.